Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Directors re-elected: Bruce Carter (Ph.D.) with 81.4% support; Jay Luly (Ph.D.) with 99.2% support, notably high vote against Carter.
ENANTA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Directors re-elected: Bruce Carter (Ph.D.) with 81.4% support; Jay Luly (Ph.D.) with 99.2% support, notably high vote against Carter
- Equity plan amended to add 1,600,000 shares to 2019 Equity Incentive Plan, approved 78% For vs 21.6% Against: moderate shareholder resistance signals dilution concern
- Say-on-pay passed with 97.2% For votes: strong endorsement of executive compensation structure
- PwC reappointed as auditor for FY2026 (ending Sept 30, 2026) with near-unanimous 99.9% approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ENANTA PHARMACEUTICALS INC 8-K filings
Get the next ENTA 8-K as it lands
Follow ENTA for push alerts, or ask the research agent what this filing means.